Alpha Paradigm Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Alpha Paradigm Partners, LLC

  • $239 Million
  • Q4 2022

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$82.16 - $96.94 $1.47 Million - $1.73 Million
17,850 New
17,850 $1.51 Million
Q2 2022

Aug 15, 2022
SELL
$71.48 - $86.85 $632,955 - $769,056
-8,855 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$74.28 - $92.69 $175,152 - $218,563
-2,358 Reduced 21.03%
8,855 $683 Million
Q4 2021

Feb 14, 2022
SELL
$71.72 - $91.47 $574,692 - $732,949
-8,013 Reduced 41.68%
11,213 $991 Million
Q3 2021

Nov 15, 2021
BUY
$74.77 - $85.47 $1.44 Million - $1.64 Million
19,226 New
19,226 $1.49 Billion

Others Institutions Holding BMRN

# of Institutions
637
Shares Held
177M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.5B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Alpha Paradigm Partners, LLC Portfolio

Follow Alpha Paradigm Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Paradigm Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Paradigm Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email